The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Global Stem Cell Therapy Market: Focus on Cardiovascular and Metabolic Disorders, 2019-2030

  • Lowest Price Guaranteed From USD 4,499

  • Published
    March 2019

  • Pages
    382

  • View Count
    4594

Example Insights

 

Overview

Cardiovascular disorders and metabolic disorders are considered to be amongst the leading causes of death worldwide. In fact, approximately one-third of the annual number of deaths across the globe are attributed to cardiovascular disorders.  In the US, the annual economic burden associated with these disorders is estimated to be over USD 500 billion. According to a study conducted by RTI International for the American Heart Association, the prevalence of cardiovascular diseases is expected to rise to 45% of the overall US population, while affiliated costs are expected to be over USD 1 trillion by 2035. Despite considerable advances in healthcare, most of the currently available treatment options for cardiovascular disorders focus on palliative care and cannot actually repair damaged cardiac tissue. Although heart transplant is a viable option to treat complex cardiovascular conditions, the waiting time associated with this alternative is excruciatingly long.

Likewise, a significant proportion of the global population suffers from diabetes or some form of metabolism related clinical condition. As per IDF Diabetes Atlas, the treatment of diabetes and related complications incurred USD 727 billion in global healthcare expenditure in 2017. In 2017, it was estimated that 425 million individuals, between the ages 20 years to 79 years, were living with diabetes across the globe, and this number is expected to increase substantially in the foreseen future. Similar to cardiovascular diseases, most of the current treatment options for metabolic disorders are indicated for only controlling / managing disease related symptoms.

Advances in cell biology and regenerative medicine have led to the development of stem cell therapies that can potentially address several unmet needs and potentially offer a cure for various cardiovascular and metabolic disorders. The field of regenerative medicine has evolved substantially in the recent past; the first stem cell therapy, called Cellgram®-AMI (2011), was approved by the Ministry of Foods and Drug Safety of Korea, for the treatment of acute myocardial infarction. Presently, two other stem cell-based treatment options, namely HeartSheet (heart failure, 2015) and Stempeucel (critical limb ischemia, 2017), are commercially available for cardiovascular disorders. For metabolic disorders, most stem cell therapy candidates are still under development. However, there is one approved product, called Strimvelis for ADA-SCID (2016). Several stakeholders are engaged in efforts to advance the development of regenerative therapies for both cardiovascular and metabolic disorders. In fact, venture capital (VC) firms and government bodies are actively funding several such ongoing research initiatives.

Scope of the Report

The “Global Stem Cell Therapy Market: Focus on Cardiovascular and Metabolic Disorders, 2019-2030” report features an extensive study of the current market landscape and the future potential of stem cell therapies in treating the aforementioned clinical conditions. The study includes all stem cell therapies that are being developed for the treatment of cardiovascular and metabolic disorders. In addition, we have provided a list of stem cell therapies being developed for stroke, a condition associated with vasculature in the brain. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of stem cell therapies with respect to target therapeutic area (cardiovascular and metabolic), phase of development (approved, phase III, phase II, phase I and preclinical / discovery), target disease indications (Cardiovascular: heart failure, myocardial infarction, critical limb ischemia, angina, peripheral arterial / vascular diseases, myocardial ischemia, myocardial fibrosis, cardiomyopathy and coronary microvascular dysfunction; Metabolic: diabetes, mucopolysaccharidosis type III, ADA-SCID, obesity, mitochondrial disorders and metachromatic leukodystrophy), source of cells (autologous and allogenic), type of stem cells (adult multipotent, adult pluripotent, embryonic multipotent and embryonic pluripotent), stem cell lineage (bone marrow, peripheral blood, adipose tissue, cardiosphere, muscle, Wharton's jelly, umbilical cord, placenta, dental pulp, cord blood and pancreas), and route of administration (intramyocardial, intramuscular, intravenous, intracoronary and implantation).
  • An analysis highlighting the key unmet needs across cardiovascular and metabolic disorders, featuring insights generated from social media posts, recent scientific publications, patient blogs and the views of contemporary key opinion leaders as expressed on online platforms.
  • An overview of the focus areas of therapy developers, including an assessment of the existing opportunity for stem cell therapies across diverse therapeutic indications.
  • An insightful company competitiveness analysis featuring a three-dimensional bubble representation, highlighting the key players in this domain on the basis of the strength of their respective product portfolios, taking into consideration the number of therapies under development, phase of development of these therapies, number of disease indications being targeted and geographical distribution of affiliated clinical trials.
  • An analysis of the partnerships that have been established in the domain in the period 2012-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, capital raised from IPOs / secondary offerings, debt financing and grants.
  • An analysis of contemporary peer-reviewed scientific research articles published during the period 2013-2018, highlighting the key focus areas of the ongoing research activity, in terms of therapeutic area, target disease indication, and stem cell lineages.
  • Comprehensive profiles of approved and late stage clinical products; each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on recommended dose, price and manufacturing process (wherever available).

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. The report includes information on (potential) sales-based revenues generated by stem cell therapies that are currently marketed or are in late stages of development for the treatment of cardiovascular and metabolic disorders. Additionally, it presents details on the likely distribution of the current and forecasted opportunity across [A] target therapeutic areas (cardiovascular and metabolic), [B] target disease indications (myocardial infarction, heart failure, critical limb ischemia, diabetes, ADA-SCID,  metachromatic leukodystrophy, and other cardiovascular and metabolic disorders ), [C] type of stem cells (adult multipotent, adult pluripotent and embryonic multipotent), [D] source of cells (autologous and allogenic), [E] stem cell lineage (bone marrow, peripheral blood and others), [F] route of administration (intramyocardial, intracoronary, intramuscular, intravenous and implantation) and [G] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of novel therapy products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem)
  • Dr. William L. Rust (Founder and Chief Executive Officer, Seraxis)
  • Xuejun H. Parsons (Chief Executive Officer, Xcelthera)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the current scenario and the likely evolution of the stem cell therapies market for cardiovascular and metabolic disorders in the short to mid-term and long term.

Chapter 3 features a brief introduction to the basic concepts related to stem cell-based therapies and the intricacies of their development and administration. In addition, it includes information on the various types of stem cell therapies (based on the source, potency and lineage of stem cells), modes of delivery and the diseases targeted by such therapies. Further, it provides details on cardiovascular and metabolic disorders, and the key indications that are being considered for treatment using stem cell therapies. Additionally, it highlights the challenges associated with stem cell therapies and provides brief insights on the anticipated future of such therapies, focusing on the treatment of cardiovascular and metabolic disorders.

Chapter 4 includes information on over 60 therapies that are currently approved / under development by industry players for the treatment of cardiovascular or metabolic disorders. It features a comprehensive analysis of pipeline therapies, highlighting the target therapeutic area (cardiovascular and metabolic), phase of development (approved, phase III, phase II, phase I and preclinical / discovery), target disease indication (Cardiovascular: heart failure, myocardial infarction, critical limb ischemia, angina, peripheral arterial / vascular diseases, myocardial ischemia, myocardial fibrosis, cardiomyopathy and coronary microvascular dysfunction; Metabolic: diabetes, mucopolysaccharidosis type III, ADA-SCID, obesity, mitochondrial disorders and metachromatic leukodystrophy), source of cells (autologous and allogenic), type of stem cells (adult multipotent, adult pluripotent, embryonic multipotent, embryonic pluripotent and others), stem cell lineage (bone marrow, peripheral blood, adipose tissue, cardiosphere, muscle, Wharton's jelly, umbilical cord, placenta, dental pulp, cord blood and pancreas), and route of administration (intramyocardial, intramuscular, intravenous, intracoronary, subcutaneous implantation and surgical implantation). Additionally, the chapter features information on over 40 therapies that are currently being developed by academic players. It also lists over 15 therapies that are being developed for the treatment of stroke.

Chapter 5 highlights the key unmet needs associated with stem cell therapies that are currently available / being developed for cardiovascular and metabolic disorders. The chapter provides detailed analysis of the various challenges and areas of concern, which were identified from views expressed by patients / experts across different platforms, such as social media posts, recent scientific publications, patient blogs, and the inputs of key opinion leaders. The chapter presents insightful word clouds, summarizing the opinions expressed across various public online portals.

Chapter 6 highlights the key target indications (myocardial infarction, heart failure, critical limb ischemia and diabetes) for which more than 7 stem cell therapies are currently under development. For each of these diseases, the chapter provides details on epidemiology, available treatment options, and the current market landscape of stem cell therapies (with respect to type of stem cell therapy, companies involved and phase of development).

Chapter 7 presents a three-dimensional bubble analysis highlighting the key companies (focused on cardiovascular and metabolic disorders) on the basis of the strength of their respective product portfolios, which takes into account the number of therapies under development, phase of development of candidate therapies, number of disease indications being targeted and geographical distribution of affiliated clinical trials.

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreement, process development agreement and other deals), and the most common forms of deals / agreements that have been established from 2012 to 2018.

Chapter 9 presents details on various investments and grants received by companies that are engaged in this domain. It includes a detailed analysis of the funding instances that have taken place during the period between 2012-2018, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 10 provides a publication analysis, highlighting the recent trends in published literature related to stem cell therapies for cardiovascular and metabolic disorders. The chapter highlights the key focus areas of the ongoing research activity, in terms of type of therapeutic area, target disease indication, and source of cells.

Chapter 11 contains detailed profiles of drugs that are recently approved or are in advanced stages of clinical development (phase III) for cardiovascular disorders. Each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on administered dose, price and manufacturing process (wherever available).

Chapter 12 contains detailed profiles of drugs that are recently approved or are in advanced stages of clinical development (phase II or above) for metabolic disorders. Each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on administered dose, price and manufacturing process (wherever available).

Chapter 13 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It provides the market estimations for therapies that are either already approved or are in the late phases of clinical development (phase III), taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price. The chapter also presents a detailed segmentation of the opportunity on the basis of [A] target therapeutic area (cardiovascular and metabolic), [B] target disease indications (myocardial infarction, heart failure, critical limb ischemia, diabetes, ADA-SCID, metachromatic leukodystrophy, and other cardiovascular and metabolic disorders), [C] type of stem cells (adult multipotent, adult pluripotent and embryonic multipotent), [D] source of cells (autologous and allogenic), [E] stem cell lineage (bone marrow, peripheral blood and others), [F] route of administration (intramyocardial, intracoronary, intramuscular, intravenous and surgical implantation) and [G] key geographical regions (North America, Europe and Asia Pacific).

Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Michel Revel (Chief Scientist, Kadimastem), Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem), Dr. William L. Rust (Founder and Chief Executive Officer, Seraxis), and Xuejun H Parsons (Chief Executive Officer, Xcelthera).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3 Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Stem Cell Therapies
3.2.1. Classification of Stem Cell Therapies by Type of Cells
3.2.1.1. Embryonic Stem Cells
3.2.1.2. Adult Stem Cells
3.2.1.3. Induced Pluripotent Stem Cells
3.2.1.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
3.2.2. Applications of Stem Cell Therapies

3.3. Overview of Cardiovascular Disorders
3.3.1. Key Indications being Investigated for Treatment with Stem Cells
3.4. Overview of Metabolic Disorders
3.4.1. Key Indications being Investigated for Treatment with Stem Cells

3.5. Administration of Stem Cell Therapies
3.6. Challenges Associated with Developing Stem Cell Therapies
3.7. Future Perspectives
3.7.1. Cardiovascular Disorders
3.7.2. Metabolic Disorders

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Marketed and Development Pipeline (Industry Players)
4.2.1. Analysis by Target Therapeutic Area
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Source of Stem Cells
4.2.4. Analysis by Type of Stem Cells
4.2.5. Analysis by Stem Cell Lineage
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Target Indication
4.2.7.1. Cardiovascular Disorders
4.2.7.2. Metabolic Disorders
4.2.8. Key Developers
4.2.9. Heptagon Representation: Analysis by Target Indication and Phase of Development of Stem Cell Therapies
4.2.10. Grid Analysis: Target Indications, Phase of Development and Source of Stem Cells

4.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Developer Landscape
4.3.1. Distribution by Focus Area
4.3.2. Distribution by Year of Establishment
4.3.3. Distribution by Size of Developer
4.3.4. Distribution by Geographical Location
4.3.5. Distribution by Location of Stem Cell Manufacturing Facilities of Developer
4.3.6. Mapping Regional Activity
4.3.7. Logo Landscape: Analysis by Size and Target Therapeutic Area

4.4. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Additional Information
4.4.1. Information on Dosage
4.4.2. Information on Designations Awarded
4.4.3. Other Therapeutic Indications under Evaluation

4.5. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Contributions from Academia
4.6. Stem Cell Therapies for Stroke

5. UNMET NEED ANALYSIS
5.1. Chapter Overview
5.2. Unmet Needs in Cardiovascular and Metabolic Disorders Market
5.2.1. Analysis of Data from Patient Blogs
5.2.1.1. Methodology
5.2.1.2. Key Insights: Cardiovascular Disorders
5.2.1.3. Key Insights: Metabolic Disorders

5.2.2. Analysis of Data from Published Literature
5.2.2.1. Methodology
5.2.2.2. Key Insights
5.2.2.2.1. Unmet Needs by Type of Indication
5.2.2.2.2. Unmet Needs by Stem Cell Lineage

5.2.3. Analysis of Data from Social Media Platforms
5.2.3.1. Methodology
5.2.3.2. Key Insights: Cardiovascular Disorders
5.2.3.3. Key Insights: Metabolic Disorders

5.2.4. Expert Opinions
5.2.4.1. Cardiovascular Disorders
5.2.4.1.1. Charles E Murry, Institute for Stem Cell and Regenerative Medicine
5.2.4.1.2. Stuart Conolly, McMaster University
5.2.4.1.3. Akshay Desai, Harvard Medical School; Sheryl Chow, Western University of Health Sciences College of Pharmacy; Scott Solomon, Harvard Medical School; Orly Vardeny, William S. Middleton Memorial VA Hospital

5.2.4.1.4. Naser M Ammash, Mayo Clinic and Joseph A Dearani, Mayo Clinic
5.2.4.1.5. Julie Anne Mitchell, Heart Foundation
5.2.4.1.6. Andre Terzic, Mayo Clinic and Atta Behfar, Mayo Clinic

5.2.4.2. Metabolic Disorders
5.2.4.2.1. Heather A Lau, Lysosomal Storage Disease Program, NYU Langone
5.2.4.2.2. Larry Hirsch, BD Diabetes Care
5.2.4.2.3. Michael Hirst, International Diabetes Federation; David Strain, University of Exeter Medical School in the UK; Xavier Cos, Sant Marti de Provençals Primary Care Centres

5.2.5. Summary of Key Unmet Needs in Cardiovascular and Metabolic Disorders

6. KEY THERAPEUTIC AREAS FOR STEM CELL THERAPIES
6.1. Chapter Overview
6.2. Cardiovascular Disorders
6.2.1. Heart Failure
6.2.1.1. Overview
6.2.1.2. Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.3.1. Pharmacological Interventions
6.2.1.3.2. Therapeutic Devices
6.2.1.3.3. Surgery
6.2.1.4. Stem Cell Therapies for Heart Failure

6.2.2. Myocardial Infarction
6.2.2.1. Overview
6.2.2.2. Epidemiology
6.2.2.3. Current Treatment Landscape
6.2.2.3.1. Pharmacological Interventions
6.2.2.3.2. Surgery
6.2.2.4. Stem Cell Therapies for Myocardial Infarction

6.2.3. Critical Limb Ischemia
6.2.3.1. Overview
6.2.3.2. Epidemiology
6.2.3.3. Current Treatment Landscape
6.2.3.3.1. Pharmacological Interventions
6.2.3.3.2. Endovascular Treatments
6.2.3.3.3. Surgery
6.2.3.4. Stem Cell Therapies for Critical Limb Ischemia

6.3. Metabolic Disorders
6.3.1. Diabetes
6.3.1.1. Overview
6.3.1.2. Epidemiology
6.3.1.3. Current Treatment Landscape
6.3.1.3.1. Insulin Therapies
6.3.1.3.2. Non-Insulin Therapies
6.3.1.3.3. Surgery
6.3.1.4. Stem Cell Therapies for Diabetes

7. COMPANY COMPETITIVENESS ANALYSIS
7.1 Chapter Overview
7.2 Methodology
7.3 Assumptions and Key Parameters
7.4 Competitiveness Analysis
7.4.1. Companies Developing Stem Cell Therapies for Cardiovascular Disorders

7.4.2. Company Developing Stem Cell Therapies for Metabolic Disorders

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnerships
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Therapeutic Area
8.3.4. Regional Analysis
8.3.4.1. Local and International Agreements
8.3.4.2. Intercontinental and Intracontinental Agreements
8.3.5. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Funding and Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas
9.3.5. Analysis by Number of Funding Instances and Amount Invested across Different Type of Stem Cells
9.3.6. Most Active Players
9.4. Concluding Remarks

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Methodology
10.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Publications
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Key Journals
10.3.3. Analysis by Type of Study
10.3.4. Analysis by Type of Disorder
10.3.4.1. Cardiovascular Disorders
10.3.4.2. Metabolic Disorders

10.3.5. Analysis by Stem Cell Lineage
10.3.6. Analysis by Stem Cell Lineage and Focused Indication
10.3.7. Emerging Areas of Focus

11. STEM CELL THERAPIES FOR CARDIOVASCULAR DISORDERS: THERAPY PROFILES
11.1. Chapter Overview
11.2. Stempeucel (Stempeutics Research)
11.2.1. Therapy Overview
11.2.2. History of Development
11.2.3. Technology Overview
11.2.4. Current Development Status
11.2.5. Key Clinical Trial Results
11.2.6. Dosing, Price and Manufacturing

11.3. Autologous Bone Marrow Concentrate (aBMC) (Cesca Therapeutics)
11.3.1. Therapy Overview
11.3.2. History of Development
11.3.3. Technology Overview
11.3.4. Current Development Status
11.3.5. Key Clinical Trial Results

11.4. BCDA-01 (BioCardia)
11.4.1. Therapy Overview
11.4.2. History of Development
11.4.3. Technology Overview
11.4.4. Current Development Status
11.4.5. Key Clinical Trial Results

11.5. BCDA-02 (BioCardia)
11.5.1. Therapy Overview
11.5.2. History of Development
11.5.3. Technology Overview
11.5.4. Current Development Status
11.5.5. Key Clinical Trial Results

11.6. CLBS14-NORDA (Caladrius Biosciences)
11.6.1. Therapy Overview
11.6.2. History of Development
11.6.3. Technology Overview
11.6.4. Current Development Status
11.6.5. Key Clinical Trial Results

11.7. MPC-150-IM (Mesoblast)
11.7.1. Therapy Overview
11.7.2. History of Development
11.7.3. Technology Overview
11.7.4. Current Development Status
11.7.5. Key Clinical Trial Results

11.8. PLX-PAD (Pluristem Therapeutics)
11.8.1. Therapy Overview
11.8.2. History of Development
11.8.3. Technology Overview
11.8.4. Current Development Status
11.8.5. Key Clinical Trial Results

12. STEM CELL THERAPIES FOR METABOLIC DISORDERS: THERAPY PROFILES
12.1. Chapter Overview
12.2. Strimvelis (Orchard Therapeutics)
12.2.1. Therapy Overview
12.2.2. History of Development
12.2.3. Technology Overview
12.2.4. Current Development Status
12.2.5. Key Clinical Trial Results
12.2.6. Dosing, Price and Manufacturing

12.3. OTL-200 (Orchard Therapeutics)
12.3.1. Therapy Overview
12.3.2. History of Development
12.3.3. Technology Overview
12.3.4. Current Development Status
12.3.5. Key Clinical Trial Results

12.4. Stem Cell Therapy (Global Cell Med)
12.4.1. Therapy Overview
12.4.2. History of Development
12.4.3. Technology Overview
12.4.4. Current Development Status
12.4.5. Key Clinical Trial Results

12.5. LMSCs (Longeveron)
12.5.1. Therapy Overview
12.5.2. History of Development
12.5.3. Current Development Status

12.6. Stem Cell Educator Therapy (Tianhe Stem Cell Biotechnologies)
12.6.1. Therapy Overview
12.6.2. History of Development
12.6.3. Technology Overview
12.6.4. Current Development Status
12.6.5. Key Clinic Trial Results

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders, 2019-2030
13.3.1. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, 2019-2030
13.3.2. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030
13.3.3. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells, 2019-2030
13.3.4. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, 2019-2030

13.4. Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, 2019-2030
13.4.1. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, 2019-2030
13.4.2. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, 2019-2030
13.4.3. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, 2019-2030
13.4.4. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, 2019-2030
13.4.5. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, 2019-2030
13.4.6. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, 2019-2030
13.4.7. Stem Cell Therapies Market for Cardiovascular Disorders: Myocardial Infarction, 2019-2030
13.4.7.1. Cellgram®-AMI (Pharmicell)
13.4.7.1.1 Target Patient Population
13.4.7.1.2. Sales Forecast
13.4.7.2.3. Sales Forecast by Geography

13.4.7.2. Cardiocell® (Cytopeutics)
13.4.7.2.1. Target Patient Population
13.4.7.2.2. Sales Forecast
13.4.7.3.3. Sales Forecast by Geography

13.4.8. Stem Cell Therapies Market for Cardiovascular Disorders: Heart Failure, 2019-2030
13.4.8.1. HeartSheet® (Terumo BCT)
13.4.8.1.1. Target Patient Population
13.4.8.1.2. Sales Forecast
13.4.8.1.3. Sales Forecast by Geography

13.4.8.2. MPC-150-IM (Mesoblast)
13.4.8.2.1. Target Patient Population
13.4.8.2.2. Sales Forecast
13.4.8.2.3. Sales Forecast by Geography

13.4.8.3. BCDA-01 (BioCardia)
13.4.8.3.1. Target Patient Population
13.4.8.3.2. Sales Forecast
13.4.8.3.3. Sales Forecast by Geography

13.4.8.4. Cardiocell® (Cytopeutics)
13.4.8.4.1. Target Patient Population
13.4.8.4.2. Sales Forecast
13.4.8.4.3. Sales Forecast by Geography

13.4.9.    Stem Cell Therapies Market for Cardiovascular Disorders: Critical Limb Ischemia, 2019-2030
13.4.9.1. Stempeucel® (Stempeutics Research)
13.4.9.1.1. Target Patient Population
13.4.9.1.2. Sales Forecast
13.4.9.1.3. Sales Forecast by Geography

13.4.9.2. PLX-PAD (Pluristem Therapeutics)
13.4.9.2.1. Target Patient Population
13.4.9.2.2. Sales Forecast
13.4.9.2.3. Sales Forecast by Geography

13.4.9.3. Cardiocell® (Cytopeutics)
13.4.9.3.1. Target Patient Population
13.4.9.3.2. Sales Forecast
13.4.9.3.3. Sales Forecast by Geography

13.4.10. Stem Cell Therapies Market for Cardiovascular Disorders: Other Indications, 2019-2030
13.4.10.1. CLBS14-NORDA (Caladrius Biosciences )
13.4.10.1.1. Target Patient Population
13.4.10.1.2. Sales Forecast
13.4.10.1.3. Sales Forecast by Geography

13.4.10.2. BCDA-02 (BioCardia)
13.4.10.2.1. Target Patient Population
13.4.10.2.2. Sales Forecast
13.4.10.2.3. Sales Forecast by Geography

13.5.    Stem Cell Therapies Market for Metabolic Disorders: Overall Market, 2019-2030
13.5.1.    Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, 2019-2030
13.5.2.    Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030
13.5.3.    Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, 2019-2030
13.5.4.    Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, 2019-2030
13.5.5.    Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cell Lineage, 2019-2030
13.5.6.    Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, 2019-2030

13.5.7.    Stem Cell Therapies Market for Metabolic Disorders: ADA-SCID, 2019-2030
13.5.7.1. Strimvelis® (Orchard Therapeutics)
13.5.7.1.1. Target Patient Population
13.5.7.1.2. Sales Forecast
13.5.7.1.3. Sales Forecast by Geography

13.5.8.    Stem Cell Therapies Market for Metabolic Disorders: Metachromatic Leukodystrophy, 2019-2030
13.5.8.1. OTL-200 (Orchard Therapeutics)
13.5.8.1.1. Target Patient Population
13.5.8.1.2. Sales Forecast
13.5.8.1.3. Sales Forecast by Geography

13.5.9.    Stem Cell Therapies Market for Metabolic Disorders: Diabetes, 2019-2030
13.5.9.1. Unnamed Stem Cell Therapy by Global Cell Med
13.5.9.1.1. Target Patient Population
13.5.9.1.2. Sales Forecast
13.5.9.1.3. Sales Forecast by Geography

14. CONCLUSION
14.1. The Treatment Landscape of Cardiovascular and Metabolic Disorders is Characterized by Several Unmet Needs; Stem Cell Therapies have Demonstrated the Potential to Offer Viable and Lasting Therapeutic Effect
14.2. The Market Features a Promising Pipeline with Several Mid and Late Stage Product Therapies, which are Mostly based on Adult Stem Cells
14.3. The Fragmented Developer Landscape Includes Small, Mid-Sized and Established Players; the Majority of Stakeholders are Presently based in North America and Europe
14.4. The Heightened Pace of Research in this Field is Evident from the Multiple R&D Agreements and the Rise in Number of Scientific Articles Published in the Recent Years
14.5. Development Efforts have Garnered the Attention of Various Private and Public Investors, Resulting in Significant Capital Investments, which are Likely to Provide the Necessary Boost to the Market’s Future Growth
14.6. Given the Impending Approval of Multiple Late Stage Molecules, the Market is Poised to Grow at a Significant Pace in the Coming Years

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Kadimastem
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Michel Revel, Chief Scientist and Galit Mazooz-Perlmuter, Business Development Manager

15.3. Seraxis
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Dr William L Rust, Founder and Chief Executive Officer

15.4. Xcelthera
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Xuejun H Parsons, Chief Executive Officer

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Stem Cell Therapies: Process of Therapy Development and Administration
Figure 3.2 Classification of Stem Cell Therapies by Type of Cells
Figure 3.3 Potential Application Areas for Stem Cell Therapies
Figure 4.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Therapeutic Area
Figure 4.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Phase of Development
Figure 4.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells
Figure 4.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells
Figure 4.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Stem Cell Lineage
Figure 4.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Route of Administration
Figure 4.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Cardiovascular Disorder 
Figure 4.8 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Metabolic Disorder 
Figure 4.9 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Key Developers
Figure 4.10 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Indication and Phase of Development
Figure 4.11 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Grid Analysis
Figure 4.12 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Focus Area of Developer
Figure 4.13 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Year of Establishment of Developer
Figure 4.14 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size of Developer
Figure 4.15 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Geographical Location of Developer
Figure 4.16 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Location of Stem Cell Therapy Manufacturing Facilities of Developer
Figure 4.17 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Mapping Regional Activity
Figure 4.18 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Logo Landscape
Figure 4.19 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Designations Awarded to Stem Cell Therapies
Figure 5.1 Unmet Needs Analysis: Overview of Methodology
Figure 5.2 Unmet Needs in Cardiovascular Disorders: Word Cloud Analysis of Data from Patient Blogs
Figure 5.3 Unmet Needs in Metabolic Disorders: Word Cloud Analysis of Data from Patient Blogs
Figure 5.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature
Figure 5.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type and Year
Figure 5.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type of Indication
Figure 5.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Stem Cell Lineage
Figure 5.8 Unmet Needs in Stem Cell Therapies for Cardiovascular Disorders: Word Cloud Analysis of Data from Social Media Tweets
Figure 5.9 Unmet Needs in Stem Cell Therapies for Metabolic Disorders: Word Cloud Analysis of Data from Social Media Tweets
Figure 5.10 Key Unmet Needs in Cardiovascular Disorders
Figure 5.11 Key Unmet Needs in Metabolic Disorders
Figure 6.1 Heart Failure: Types
Figure 6.2 Heart Failure: Risk Factors
Figure 6.3 Heart Failure: Symptoms
Figure 6.4 Heart Failure: Distribution of Stem Cell Therapies by Phase of Development and Type of Stem Cells
Figure 6.5 Myocardial Infarction: Risk Factors
Figure 6.6 Myocardial Infarction: Distribution by Phase of Development and Type of Stem Cells
Figure 6.7 Critical Limb Ischemia: Symptoms
Figure 6.8 Critical Limb Ischemia: Risk Factors
Figure 6.9 Critical Limb Ischemia: Distribution of Stem Cell Therapies by Phase of Development and Type of Stem Cells
Figure 6.10 Diabetes: Risk Factors
Figure 6.11 Diabetes: Currently Available Non-Insulin Therapies 
Figure 6.12 Diabetes: Distribution by Phase of Development and Type of Stem Cells
Figure 7.1 Competitiveness Analysis of Companies Developing Stem Cell Therapies for Cardiovascular Disorders
Figure 7.2 Competitiveness Analysis of Companies Developing Stem Cell Therapies for Metabolic Disorders
Figure 8.1 Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area 
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
Figure 8.5 Partnerships and Collaborations : Activity of Big Pharmaceutical Companies
Figure 8.6 Partnerships and Collaborations: Regional Distribution
Figure 8.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 8.8 Partnerships and Collaborations: Most Active Players
Figure 9.1 Funding and Investments: Distribution by Year of Establishment and Type of Funding, 2012-2018
Figure 9.2 Funding and Investments: Cumulative Number of Instances by Year, 2012-2018
Figure 9.3 Funding and Investments: Cumulative Amount Invested by Year, 2012-2018 (USD Million)
Figure 9.4 Funding and Investments: Distribution by Type of Funding
Figure 9.5 Funding and Investments: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 9.6 Funding and Investments: Distribution of Number of Funding Instances by Year across Major Therapeutic Areas, 2012-2018
Figure 9.7 Funding and Investments: Amount Invested by Year across Major Therapeutic Areas, 2012-2018
Figure 9.8 Funding and Investments: Distribution of Number of Instances by Type of Funding, 2012-2015 and Post 2015
Figure 9.9 Funding and Investments: Amount Invested by Type of Funding, 2012-2015 and Post 2015
Figure 9.10 Funding and Investments: Amount Invested by Year of Investments in Various Type of Stem Cells, 2012-2018
Figure 9.11 Funding and Investments: Most Active Players 
Figure 9.12 Funding and Investments Summary
Figure 10.1 Publications: Cumulative Trend by Year, 2013-2018
Figure 10.2 Publications: Most Popular Journals
Figure 10.3 Publications: Distribution by Type of Study
Figure 10.4 Publications: Distribution by Type of Disorder
Figure 10.5 Publications: Distribution by Type of Cardiovascular Disorders
Figure 10.6 Publications: Distribution by Type of Metabolic Disorders
Figure 10.7 Publications: Distribution by Stem Cell Lineage
Figure 10.8 Publications: Distribution of Articles Focused on Bone Marrow Derived Stem Cells by Indication 
Figure 10.9 Publications: Distribution of Articles Focused on Cardiosphere Derived Stem Cells by Indication 
Figure 10.10 Publications: Distribution of Articles Focused on Adipose Derived Stem Cells by Indication 
Figure 10.11 Publications: Emerging Areas
Figure 11.1 Stempeucel: History of Development
Figure 11.2 Stempeucel: Development / Manufacturing Process
Figure 11.3 aBMC by Cesca Therapeutics: History of Development 
Figure 11.4 aBMC by Cesca Therapeutics:  Development / Manufacturing Process
Figure 11.5 BCDA-01: History of Development  
Figure 11.6 BCDA-01: Development / Manufacturing Process
Figure 11.7 BCDA-02: History of Development  
Figure 11.8 CLBS14-NORDA: History of Development
Figure 11.9 CLBS14-NORDA: Development / Manufacturing Process
Figure 11.10 MPC-150-IM:  History of Development
Figure 11.11 MPC-150-IM: Development / Manufacturing Process
Figure 11.12 PLX-PAD: Mechanism of Action
Figure 11.13 PLX-PAD: History of Development
Figure 11.14 PLX-PAD: Development / Manufacturing Process
Figure 12.1 Strimvelis: History of Development 
Figure 12.2 Strimvelis: Development / Manufacturing Process
Figure 12.3 Unnamed Stem Cell Therapy by Global Cell Med: Development / Manufacturing Process
Figure 12.4 Stem Cell Educator System: History of Development  
Figure 12.5 Stem Cell Educator System: Development / Manufacturing Process
Figure 13.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, 2019-2030 (USD Million) 
Figure 13.2 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, 2019-2030 (USD Million)
Figure 13.3 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
Figure 13.4 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells, 2019-2030 (USD Million)
Figure 13.5 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, 2019-2030 (USD Million)
Figure 13.6 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, 2019-2030 (USD Million)
Figure 13.7 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, 2019-2030 (USD Million)
Figure 13.8 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
Figure 13.9 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 13.10 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, 2019-2030 (USD Million)
Figure 13.11 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, 2019-2030 (USD Million)
Figure 13.12 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, 2019-2030 (USD Million)
Figure 13.13 Cellgram®-AMI: Target Patient Population
Figure 13.14 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.15 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.16 Cardiocell®: Target Patient Population
Figure 13.17 Cardiocell®: Sales Forecast for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.18 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.19 HeartSheet®: Target Patient Population
Figure 13.20 HeartSheet®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.21 HeartSheet®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.22 MPC-150-IM (Rexlemestrocel-L): Target Patient Population
Figure 13.23 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.24 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.25 BCDA-01: Target Patient Population
Figure 13.26 BCDA-01: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.27 BCDA-01: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.28 Cardiocell®: Target Patient Population
Figure 13.29 Cardiocell®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.30 Cardiocell®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.31 Stempeucel®: Target Patient Population
Figure 13.32 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.33 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.34 PLX-PAD: Target Patient Population
Figure 13.35 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.36 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.37 Cardiocell®: Target Patient Population
Figure 13.38 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.39 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.40 CLBS14-NORDA: Target Patient Population
Figure 13.41 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.42 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.43 BCDA-02: Target Patient Population
Figure 13.44 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.45 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.46 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, 2019-2030 (USD Million)
Figure 13.47 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, 2019-2030 (USD Million)
Figure 13.48 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
Figure 13.49 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 13.50 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, 2019-2030 (USD Million)
Figure 13.51 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, 2019-2030 (USD Million)
Figure 13.52 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, 2019-2030 (USD Million)
Figure 13.53 Strimvelis®: Target Patient Population
Figure 13.54 Strimvelis®: Sales Forecast for ADA-SCID, Till 2030 (USD Million)
Figure 13.55 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Till 2030 (USD Million)
Figure 13.56 OTL-200: Sales Forecast for ADA-SCID, Till 2030 (USD Million)
Figure 13.57 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Till 2030 (USD Million)
Figure 13.58 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Till 2030 (USD Million)
Figure 13.59 Unnamed Stem Cell Therapy by Global Cell Med: Target Patient Population
Figure 13.60 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Till 2030 (USD Million)
Figure 13.61 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast by Geography for Type 1 Diabetes, Till 2030 (USD Million)
Figure 14.1 Overall Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Conservative, Base and Optimistic Forecast Scenarios, 2020 and 2030 (USD Million)

List of Tables

Table 4.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Marketed and Development Pipeline (Industry Players)
Table 4.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Developer Overview
Table 4.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Information on Dose of Stem Cell Therapies
Table 4.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Information on Designations Awarded to Stem Cell Therapies
Table 4.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Other Indications Under Evaluation
Table 4.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Pipeline Overview (Academic Players)
Table 4.7 Stem Cell Therapies for Stroke
Table 5.1 Unmet Needs in Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Sources / Blog Portals
Table 6.1 Heart Failure: List of Marketed Drugs
Table 6.2 Heart Failure: List of Stem Cell Therapies 
Table 6.3 Myocardial Infarction: List of Marketed Drugs
Table 6.4 Myocardial Infarction: List of Stem Cell Therapies
Table 6.5 Peripheral Arterial Diseases: List of Marketed Drugs
Table 6.6 Critical Limb Ischemia: List of Stem Cell Therapies
Table 6.7 Diabetes: Current Treatment Landscape
Table 6.8 Diabetes: List of Stem Cell Therapies
Table 8.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Partnerships and Collaborations, 2012-2018
Table 9.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Funding and Investments, 2012-2018
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 Stem Cell Therapy for Cardiovascular and Metabolic Disorders: List of Publications, 2013-2018
Table 11.1 Stempeucel: List / Details of Clinical Trials
Table 11.2 aBMC by Cesca Therapeutics: Clinical TrialsTable 11.3 BCDA-01: List / Details of Clinical Trials
Table 11.4 BCDA-02: List / Details of Clinical Trials
Table 11.5 CLBS14-NORDA: List / Details of Clinical Trials
Table 11.6 MPC-150-IM: List / Details of Clinical Trials
Table 11.7 PLX-PAD: List / Details of Clinical Trials
Table 12.1 Strimvelis: List / Details of Clinical Trials
Table 12.2 OTL-200: List / Details of Clinical Trials
Table 12.3 Stem Cell Therapy by Global Cell Med: Clinical Trials
Table 12.4 LMSCs: List / Details of Clinical Trials
Table 12.5 Stem Cell Educator Therapy: List / Details of Clinical Trials
Table 13.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Forecasted Therapies
Table 15.1 Kadimastem: Key Highlights
Table 15.2 Seraxis: Key Highlights
Table 15.3 Xcelthera: Key Highlights
Table 16.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Therapeutic Area
Table 16.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Phase of Development
Table 16.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells
Table 16.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells
Table 16.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Stem Cell Lineage
Table 16.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Route of Administration
Table 16.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Cardiovascular Disorder 
Table 16.8 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Metabolic Disorder 
Table 16.9 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Key Developers
Table 16.10 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Focus Area of Developer
Table 16.11 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Year of Establishment of Developer
Table 16.12 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size of Developer
Table 16.13 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Geographical Location of Developer
Table 16.14 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Location of Stem Cell Therapy Manufacturing Facilities of Developer
Table 16.15 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Designations Awarded to Stem Cell Therapies
Table 16.16 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature
Table 16.17 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type and Year
Table 16.18 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type of Indication
Table 16.19 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Stem Cell Lineage
Table 16.20 Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
Table 16.21 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.22 Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area 
Table 16.23 Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
Table 16.24 Partnerships and Collaborations: Regional Distribution
Table 16.25 Partnerships and Collaborations: Most Active Players
Table 16.26 Funding and Investments: Cumulative Number of Instances by Year, 2012-2018
Table 16.27 Funding and Investments: Cumulative Amount Invested by Year, 2012-2018 (USD Million)
Table 16.28 Funding and Investments: Distribution by Type of Funding
Table 16.29 Funding and Investments: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 16.30 Funding and Investments: Distribution of Number of Funding Instances by Year across Major Therapeutic Areas, 2012-2018
Table 16.31 Funding and Investments: Amount Invested by Year across Major Therapeutic Areas, 2012-2018
Table 16.32 Funding and Investments: Distribution of Number of Instances by Type of Funding, 2012-2015 and Post 2015
Table 16.33 Funding and Investments: Amount Invested by Type of Funding, 2012-2015 and Post 2015
Table 16.34 Funding and Investments: Most Active Players
Table 16.35 Publications: Cumulative Trend by Year, 2013-2018
Table 16.36 Publications: Most Popular Journals
Table 16.37 Publications: Distribution by Type of Study
Table 16.38 Publications: Distribution by Type of Disorder
Table 16.39 Publications: Distribution by Type of Cardiovascular Disorders
Table 16.40 Publications: Distribution by Type of Metabolic Disorders
Table 16.41 Publications: Distribution by Stem Cell Lineage
Table 16.42 Publications: Distribution of Articles Focused on Bone Marrow Derived Stem Cells by Indication 
Table 16.43 Publications: Distribution of Articles Focused on Cardiosphere Derived Stem Cells by Indication 
Table 16.44 Publications: Distribution of Articles Focused on Adipose Derived Stem Cells by Indication    
Table 16.45 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)    
Table 16.46 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
Table 16.47 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.48 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Conservative Scenario, 2019-2030 (USD Million)
Table 16.49 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Base Scenario, 2019-2030 (USD Million)
Table 16.50 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.51 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.52 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.53 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.54 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.55 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.56 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.57 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 16.58 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 16.59 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.60 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
Table 16.61 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
Table 16.62 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.63 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Conservative Scenario, 2019-2030 (USD Million)
Table 16.64 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Base Scenario, 2019-2030 (USD Million)
Table 16.65 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.66 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.67 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.68 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.69 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Conservative Scenario, 2019-2030 (USD Million)
Table 16.70 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Base Scenario, 2019-2030 (USD Million)
Table 16.71 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.72 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.73 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.74 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.75 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Conservative Scenario, 2019-2030 (USD Million)
Table 16.76 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Base Scenario, 2019-2030 (USD Million)
Table 16.77 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.78 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 16.79 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 16.80 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.81 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.82 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.83 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.84 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.85 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.86 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.87 Cardiocell®: Sales Forecast for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.88 Cardiocell®: Sales Forecast for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.89 Cardiocell®: Sales Forecast for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.90 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.91 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.92 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.93 HeartSheet®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.94 HeartSheet®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.95 HeartSheet®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.96 HeartSheet®: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.97 HeartSheet®: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.98 HeartSheet®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.99 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.100 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.101 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.102 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.103 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.104 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.105 BCDA-01: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.106 BCDA-01: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.107 BCDA-01: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.108 BCDA-01: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.109 BCDA-01: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.110 BCDA-01: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.111 Cardiocell®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.112 Cardiocell®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.113 Cardiocell®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.114 Cardiocell®: Sales Forecast by Geography for Heart Failure, Conservative Scenario Till 2030 (USD Million)
Table 16.115 Cardiocell®: Sales Forecast by Geography for Heart Failure, Base Scenario Till 2030 (USD Million)
Table 16.116 Cardiocell®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario Till 2030 (USD Million)
Table 16.117 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.118 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.119 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.120 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.121 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.122 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.123 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.124 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.125 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.126 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.127 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.128 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.129 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.130 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.131 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.132 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.133 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.134 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.135 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.136 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.137 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.138 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.139 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.140 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.141 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.142 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.143 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.144 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.145 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, base Scenario, Till 2030 (USD Million)
Table 16.146 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million) 
Table 16.147 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.148 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.149 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.150 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.151 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.152 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.153 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
Table 16.154 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
Table 16.155 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.156 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Conservative Scenario, 2019-2030 (USD Million)
Table 16.157 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Base Scenario, 2019-2030 (USD Million)
Table 16.158 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.159 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.160 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.161 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.162 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Conservative Scenario, 2019-2030 (USD Million)
Table 16.163 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Base Scenario, 2019-2030 (USD Million)
Table 16.164 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.165 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.166 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.167 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.168 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Conservative Scenario, 2019-2030 (USD Million)
Table 16.169 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Base Scenario, 2019-2030 (USD Million)
Table 16.170 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.171 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 16.172 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 16.173 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.174 Strimvelis®: Sales Forecast for ADA-SCID, Conservative Scenario, Till 2030 (USD Million)
Table 16.175 Strimvelis®: Sales Forecast for ADA-SCID, Base Scenario, Till 2030 (USD Million)
Table 16.176 Strimvelis®: Sales Forecast for ADA-SCID, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.177 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Conservative Scenario, Till 2030 (USD Million)
Table 16.178 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Base Scenario, Till 2030 (USD Million)
Table 16.179 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.180 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Conservative Scenario, Till 2030 (USD Million)
Table 16.181 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Base Scenario, Till 2030 (USD Million)
Table 16.182 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.183 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Conservative Scenario, Till 2030 (USD Million)
Table 16.184 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Base Scenario, Till 2030 (USD Million)
Table 16.185 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.186 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Conservative Scenario, Till 2030 (USD Million)
Table 16.187 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Base Scenario, Till 2030 (USD Million)
Table 16.188 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.189 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast by Geography for Type 1 Diabetes, Conservative Scenario, Till 2030 (USD Million)
Table 16.190 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast by Geography for Type 1 Diabetes, Base Scenario, Till 2030 (USD Million)
Table 16.191 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast by Geography for Type 1 Diabetes, Opportunistic Scenario, Till 2030 (USD Million)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3P Biopharmaceuticals
  2. 4BIO Capital
  3. 6 Dimensions Capital
  4. Advanced Stem Cell Rx
  5. Agent Capital
  6. Aldagen
  7. Altaco XXI
  8. ALTuCELL
  9. Andalusian Initiative for Advanced Therapies
  10. Ankara University
  11. apceth Biopharma
  12. ARCH Venture Partners
  13. ArrowMark Partners
  14. ASAP Ventures
  15. Aspire Capital
  16. Asset Management Partners
  17. Assistance Publique - Hôpitaux de Paris
  18. Athersys
  19. Baillie Gifford
  20. Bain Capital Life Sciences
  21. Barts Health NHS Trust 
  22. Batipart 
  23. Beyond Type 1
  24. BioCardia
  25. BioLamina
  26. BioRestorative Therapies
  27. Boston Children’s Hospital
  28. Boyalife Group
  29. Bpifrance
  30. Broadfin Capital
  31. BTIG
  32. Caladrius Biosciences
  33. California Institute for Regenerative Medicine 
  34. Capricor Therapeutics 
  35. CardioCell
  36. Celgene
  37. Celixir
  38. CellPraxis Bioengeneering
  39. CellProthera
  40. Celyad
  41. Center for Cellular Technologies 
  42. Centre for Commercialization of Regenerative Medicine
  43. Center for iPS Cell Research and Application 
  44. Cesca Therapeutics
  45. Cha Bio&Diostech
  46. Chinese Academy of Sciences
  47. Cipla
  48. Cognate BioServices
  49. Colorado Center for Reproductive Medicine 
  50. Columbia University
  51. Compass Biomedical
  52. CORD:USE
  53. CORESTEM 
  54. Cormorant Asset Management
  55. Cowen Healthcare Investments
  56. CRISPR Therapeutics
  57. CTI Clinical Trial and Consulting Services
  58. CureDuchenne Ventures
  59. Cytopeutics
  60. Cytori Therapeutics
  61. Dai Nippon Printing
  62. Daiichi Sankyo
  63. Deerfield Management
  64. Defymed
  65. Driehaus Capital Management 
  66. DUKE National University Singapore Medical School
  67. East Capital
  68. East West Capital Partners
  69. Eli Lilly
  70. Evotec
  71. Federal Research And Clinical Center 
  72. Flagship Pioneering
  73. Foresite Capital
  74. F-Prime Capital 
  75. Fuzhou General Hospital
  76. General American Capital Partners
  77. Ghost Tree Capital
  78. GlaxoSmithKline
  79. Global Cell Med
  80. Gore
  81. Great Ormond Street Hospital 
  82. Green Cross Health
  83. GRI Fund
  84. H.C. Wainwright
  85. H2M Capital 
  86. Harvard Stem Cell Institute
  87. Healios
  88. Hercules Capital
  89. Hospital La Paz Institute for Health Research
  90. Hunton & Williams
  91. Imperial College London
  92. Innovative Cellular Therapeutics
  93. Innovative Medical Management
  94. Invetech
  95. IRCCS San Raffaele
  96. Israel Innovation Authority
  97. Janssen Biotech
  98. JDRF
  99. Johann Wolfgang Goethe University Hospital
  100. Johnson & Johnson
  101. Johnson Trust
  102. Juda Capital
  103. Kadimastem
  104. Kempen
  105. Ladenburg Thalmann
  106. Leerink Partners
  107. Lifecell
  108. Lincoln Park Capital
  109. Lorem Vascular
  110. LSK Partners
  111. Ludwig Boltzmann Institute
  112. M D Anderson Cancer Center
  113. Magna Equities
  114. Maryland Stem Cell Research Fund
  115. Massachusetts General Hospital
  116. McEwen Stem Cell Institute 
  117. Medical University of Silesia
  118. Medical University of South Carolina
  119. Medison Ventures
  120. Medisun International
  121. MedStar Heart & Vascular Institute
  122. Medtronic
  123. Medytox
  124. Mesoblast
  125. MidCap Financial
  126. Miltenyi Biotec
  127. Minovia Therapeutics
  128. Moraga Biotechnology
  129. MPM Capital
  130. Nanjing Drum Tower Hospital
  131. National Cardiovascular Center Harapan Kita Hospital
  132. National Heart Centre Singapore 
  133. National Heart, Lung, and Blood Institute
  134. National Institute of Diabetes and Digestive and Kidney Diseases 
  135. National Institutes of Health
  136. National University of Ireland
  137. Nile Therapeutics
  138. Novartis
  139. Novo Nordisk 
  140. Nuo Therapeutics 
  141. Okayama University
  142. Orchard Therapeutics
  143. ORI Healthcare Fund
  144. Osaka University
  145. Oxford BioMedica
  146. Oxford Finance
  147. Pavilion Capital
  148. Peking University Aerospace Centre Hospital
  149. Perceptive Advisors
  150. PharmaCell
  151. Pharmicell
  152. Piper Jaffray
  153. Pontifical Catholic University of Paraná
  154. Postgraduate Institute of Medical Education and Research
  155. Progenitor Cell Therapy 
  156. Queen Mary University of London
  157. RA Capital Management
  158. ReNeuron
  159. RHEACELL
  160. Rigshospitalet
  161. Royal Brompton and Harefield NHS Foundation Trust
  162. Royan Institute
  163. RTW Investments
  164. Sabby Capital
  165. Sakakibara Heart Institute
  166. Sanderling Ventures
  167. Sanford Health
  168. Sanofi
  169. SC&H Capital
  170. Sclnow Biotechnology
  171. Semma Therapeutics
  172. Seraxis
  173. Sernova
  174. Shanghai 10th People's Hospital
  175. Shanghai Biotechnology
  176. Shavit Capital 
  177. Shire
  178. Sigilon Therapeutics
  179. Silicon Valley Bank
  180. Sinopharm Capital
  181. Sosei
  182. South China Research Center for Stem Cell and Regenerative Medicine
  183. Sphera Global Health Care
  184. SPS Cardio
  185. Stem Cell and Regenerative Medicine Institute 
  186. Stem cell unit, Van Hanh General Hospital
  187. Stem Cells Arabia
  188. Stempeutics Research 
  189. SymbioCellTech
  190. Takeda Pharmaceutical 
  191. Tasly Pharmaceutical
  192. Tel Aviv University
  193. Temasek
  194. Terumo BCT
  195. The Champ Foundation
  196. Thomson Medical Centre
  197. Tianhe Stem Cell Biotechnologies
  198. Tiger X Medical
  199. TMC Life Sciences
  200. Topstone Research
  201. Toulouse University Hospital 
  202. TPG
  203. U.S. Stem Cell
  204. University Health Network
  205. University Hospital, Clermont-Ferrand
  206. University Hospital, Ostrava
  207. University Medical Center, Utrecht
  208. University Medical Centre Ljubljana
  209. University of Bristol
  210. University of California
  211. University of Florence
  212. University of Glasgow
  213. University of Jordan
  214. University of Kentucky
  215. University of Manchester
  216. University of Miami
  217. University of Minnesota - Clinical and Translational Science Institute
  218. University of Pennsylvania
  219. University of Texas Health Science Center, Houston
  220. University of Ulm
  221. University of Utah
  222. Venrock
  223. Vericel 
  224. ViaCyte
  225. Vinmec Research Institute of Stem Cell and Gene Technology
  226. Viscofan BioEngineering
  227. Wood Capital
  228. Wu Capital
  229. Xcelthera
  230. Zheshang Venture Capital 

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com